AURA Aura Biosciences Forecast, Technical & Fundamental Analysis
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer... Show more
AURA is expected to report earnings to fall 23.44% to -36 cents per share on November 05
Q3'26
Est.
$-0.37
Q2'26
Missed
by $0.07
Q1'26
Missed
by $0.06
Q4'25
Beat
by $0.09
Q3'25
Beat
by $0.06
The last earnings report on August 11 showed earnings per share of -47 cents, missing the estimate of -40 cents. With 267.84K shares outstanding, the current market capitalization sits at 767.42M.
A.I.dvisor indicates that over the last year, AURA has been loosely correlated with MLTX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if AURA jumps, then MLTX could also see price increases.
AURA in -4.27% downward trend, declining for three consecutive days on August 28, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where AURA declined for three days, in of 297 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for AURA moved out of overbought territory on August 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AURA as a result. In of 109 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for AURA turned negative on August 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
AURA moved above its 50-day moving average on July 23, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AURA crossed bullishly above the 50-day moving average on July 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AURA advanced for three days, in of 271 cases, the price rose further within the following month. The odds of a continued upward trend are .
AURA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 139 cases where AURA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.434) is normal, around the industry mean (20.149). P/E Ratio (0.000) is within average values for comparable stocks, (22.729). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.796). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (429.250).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AURA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
